• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新冠病毒感染使用奈玛特韦-利托那韦(帕罗韦德)治疗后寻求医疗护理的风险因素:“症状反弹”

Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: "Symptom Rebound".

作者信息

Bhargava Ashish, Szpunar Susan, Sharma Mamta, Saravolatz Louis

机构信息

Department of Medicine, Thomas Mackey Center for Infectious Disease Research, Henry Ford St. John Hospital, 19251 Mack Avenue, Suite 340, Grosse Pointe Woods, MI 48236, USA.

出版信息

Viruses. 2025 May 29;17(6):782. doi: 10.3390/v17060782.

DOI:10.3390/v17060782
PMID:40573371
Abstract

Nirmatrelvir plus ritonavir (NPR) has been approved for treating mild to moderate COVID-19 in high-risk adults but concerns about rebound effects have limited its use. This study aimed to identify individuals at risk of seeking medical care among high-risk non-hospitalized patients treated with NPR from 1 January 2022 to 31 December 2022, at our institution. Our outcome variable was the composite of subsequent evaluation in the Emergency Department or inpatient admission within four weeks of their NPR treatment. Of 369 patients who received NPR treatment, the mean (SD) age was 59.3 (±13.8) years; 64% (236) were female, and 77.7% (281) were white. The incidence of the composite event was 6.8% (25/369). In multivariable logistic regression, factors for seeking medical care following NPR treatment were female sex (OR 4.6; 95% CI 1.4-15.3; = 0.013), myocardial infarction (OR 4.1; 95% CI 1.4-11.8; = 0.011), chronic lung disease (CLD) except asthma and chronic obstructive pulmonary disease (COPD) (OR = 3.9, 95% CI 1.1-13.5; = 0.03), and diabetes mellitus with complications (OR 6.9; 95% CI 2.0-23.3; = 0.002) while alcohol users (OR 0.39; 95% CI 0.2-0.9; = 0.038) were less likely to seek medical care. Larger cohorts are necessary to further assess and confirm these risk factors.

摘要

奈玛特韦片/利托那韦片组合包装(NPR)已被批准用于治疗高危成人的轻至中度新冠肺炎,但对反弹效应的担忧限制了其使用。本研究旨在确定2022年1月1日至2022年12月31日在我们机构接受NPR治疗的高危非住院患者中可能寻求医疗护理的个体。我们的结局变量是在接受NPR治疗后四周内急诊复诊或住院的综合情况。在369例接受NPR治疗的患者中,平均(标准差)年龄为59.3(±13.8)岁;64%(236例)为女性,77.7%(281例)为白人。综合事件的发生率为6.8%(25/369)。在多变量逻辑回归分析中,NPR治疗后寻求医疗护理的因素包括女性(比值比4.6;95%置信区间1.4 - 15.3;P = 0.013)、心肌梗死(比值比4.1;95%置信区间1.4 - 11.8;P = 0.011)、除哮喘和慢性阻塞性肺疾病(COPD)外的慢性肺病(CLD)(比值比 = 3.9,95%置信区间1.1 - 13.5;P =  0.03)以及伴有并发症的糖尿病(比值比6.9;95%置信区间2.0 - 23.3;P = 0.002),而饮酒者寻求医疗护理的可能性较小(比值比0.39;95%置信区间0.2 - 0.9;P = 0.038)。需要更大的队列来进一步评估和确认这些风险因素。

相似文献

1
Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: "Symptom Rebound".新冠病毒感染使用奈玛特韦-利托那韦(帕罗韦德)治疗后寻求医疗护理的风险因素:“症状反弹”
Viruses. 2025 May 29;17(6):782. doi: 10.3390/v17060782.
2
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦片/利托那韦片组合包装用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2.
3
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦/利托那韦片用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD015395. doi: 10.1002/14651858.CD015395.pub3.
4
SARS-CoV-2 infection rebound among patients receiving antiviral agents, convalescent plasma, or no treatment: a systematic review with meta-analysis.接受抗病毒药物、恢复期血浆或未接受治疗的患者中 SARS-CoV-2 感染复发:系统评价与荟萃分析。
Blood Transfus. 2024 Nov;22(6):537-550. doi: 10.2450/BloodTransfus.764. Epub 2024 May 27.
5
Real-world effectiveness and economic analysis of nirmatrelvir/ritonavir, remdesivir, and molnupiravir for treatment of COVID-19 among ambulatory patients in Thailand.泰国门诊患者中使用奈玛特韦/利托那韦、瑞德西韦和莫努匹拉韦治疗新冠病毒病的真实世界有效性和经济分析
J Infect Public Health. 2025 Aug;18(8):102826. doi: 10.1016/j.jiph.2025.102826. Epub 2025 May 13.
6
Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.奈玛特韦片/利托那韦片组合包装用于新冠病毒感染的成年门诊患者(接种或未接种疫苗)。
N Engl J Med. 2024 Apr 4;390(13):1186-1195. doi: 10.1056/NEJMoa2309003.
7
Real-world effectiveness of simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 during the omicron wave in China: a retrospective cohort study.在中国奥密克戎毒株流行期间,住院的新冠肺炎患者中,西米诺特韦-利托那韦与奈玛特韦-利托那韦的真实世界有效性:一项回顾性队列研究
BMC Infect Dis. 2025 Jul 1;25(1):840. doi: 10.1186/s12879-025-11195-9.
8
Association of Nirmatrelvir/Ritonavir and the Risk of Long COVID Among US Adults: A Multicenter Retrospective Cohort Study.奈玛特韦/利托那韦与美国成年人长期新冠风险的关联:一项多中心回顾性队列研究。
J Med Virol. 2025 Jul;97(7):e70494. doi: 10.1002/jmv.70494.
9
Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial.尼马瑞韦/利托那韦片和成年人 SARS-CoV-2 感染后后遗症症状:STOP-PASC 随机临床试验。
JAMA Intern Med. 2024 Sep 1;184(9):1024-1034. doi: 10.1001/jamainternmed.2024.2007.
10
Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.奈玛特韦/利托那韦口服作为新冠病毒暴露后预防。
N Engl J Med. 2024 Jul 18;391(3):224-234. doi: 10.1056/NEJMoa2309002.

引用本文的文献

1
Pharmacological and Adjunctive Management of Non-Hospitalized COVID-19 Patients During the Omicron Era: A Systematic Review and Meta-Analysis.奥密克戎时代非住院COVID-19患者的药物治疗及辅助管理:一项系统评价与荟萃分析
Viruses. 2025 Aug 16;17(8):1128. doi: 10.3390/v17081128.

本文引用的文献

1
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals.使用和未使用COVID-19口服抗病毒药物时的SARS-CoV-2病毒反弹情况
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1357-1364. doi: 10.15585/mmwr.mm7251a1.
2
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study.SARS-CoV-2 病毒学反弹与奈玛特韦-利托那韦治疗:一项观察性研究。
Ann Intern Med. 2023 Dec;176(12):1577-1585. doi: 10.7326/M23-1756. Epub 2023 Nov 14.
3
Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
奈玛特韦/利托那韦片或莫努匹韦使用与奥密克戎感染的重症结局。
JAMA Netw Open. 2023 Sep 5;6(9):e2335077. doi: 10.1001/jamanetworkopen.2023.35077.
4
FDA Grants Full Approval to Paxlovid, COVID-19 Antiviral Treatment.美国食品药品监督管理局(FDA)完全批准新冠病毒抗病毒治疗药物帕罗韦德(Paxlovid)。
JAMA. 2023 Jun 27;329(24):2118. doi: 10.1001/jama.2023.9925.
5
COVID-19 in Patients with Chronic Lung Disease.慢性肺病患者中的 COVID-19 。
Clin Chest Med. 2023 Jun;44(2):385-393. doi: 10.1016/j.ccm.2022.11.013. Epub 2022 Nov 22.
6
Factors associated with viral rebound among COVID-19 patients receiving oral antivirals.口服抗病毒药物治疗的 COVID-19 患者病毒反弹的相关因素。
J Formos Med Assoc. 2023 Aug;122(8):766-775. doi: 10.1016/j.jfma.2023.02.008. Epub 2023 Mar 8.
7
Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir.接受奈玛特韦/利托那韦或莫努匹拉韦治疗新冠病毒的慢性淋巴细胞白血病患者中新冠病毒感染的反弹情况。
Leuk Lymphoma. 2023 May;64(5):1054-1056. doi: 10.1080/10428194.2023.2183732. Epub 2023 Mar 13.
8
The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated Controls.2019 年冠状病毒病反弹研究:一项前瞻性队列研究,评估接受奈玛特韦利托那韦与未治疗对照相比的参与者的病毒和症状反弹差异。
Clin Infect Dis. 2023 Jul 5;77(1):25-31. doi: 10.1093/cid/ciad102.
9
Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.香港一项全人群回顾性队列研究显示,接受口服抗病毒药物治疗的 COVID-19 住院患者病毒载量反弹。
Lancet Infect Dis. 2023 Jun;23(6):683-695. doi: 10.1016/S1473-3099(22)00873-8. Epub 2023 Feb 13.
10
Identifying pre-existing conditions and multimorbidity patterns associated with in-hospital mortality in patients with COVID-19.识别与 COVID-19 患者住院死亡率相关的预先存在的疾病和多种合并症模式。
Sci Rep. 2022 Oct 15;12(1):17313. doi: 10.1038/s41598-022-20176-w.